The market for radiopharmaceuticals is expected to witness a healthy growth during the forecast period, owing to an increase in technology-driven healthcare facilities and rise in costs of medical care in Japan. Radiopharmaceuticals are clinical medications that display radioactivity. The market is currently driven by the rising need for novel radiopharmaceuticals. The diagnostics and rehabs segments of the Japan radiopharmaceuticals market are anticipated to expand at a healthy rate during the forecast period.
The significant driving factor of the Japan radiopharmaceuticals market is the rise in the senior population that are more vulnerable to cancer as well as various other diseases. In addition, the rising price of healthcare as well as the advancement of new radiopharmaceuticals to treat cancer cells have driven the market expansion. Technological improvements in radiopharmaceuticals have substantially improved the detection as well as diagnosis of conditions, providing precise person analyses and also boosting therapy effectiveness in the country. Radiopharmaceuticals are currently being utilized to diagnose and also deal with cancer, heart diseases, as well as neurological problems, further creating better opportunities for the market growth.
Furthermore, enhancing R&D for the improvement of radiopharmaceuticals, elevating understanding about nuclear medicine, and the rise in the authorization of new radiopharmaceutical drugs are some of the factors driving the market growth.
Nevertheless, the particulars of the production procedure of radiopharmaceuticals and the rigorous guidelines & protocols within the medical care system of the country are a few of the restraining factors hampering the growth of the Japan radiopharmaceuticals market.
The increase in the recognition of nuclear medication and its potential application for disease medical diagnosis has opened various opportunities for the Kyoto radiopharmaceuticals market. With technological improvements such as electronic tomography and positron discharge tomography (PET) being extensively approved, radiopharmaceuticals present significant possibility to the nuclear medicine market. This consequently has paved the way for R&D tasks in this market. Furthermore, the rising frequency of cancer as well as the authorization of brand-new cancer medicines are anticipated to boost the growth of the market.
In addition, the raising variety of nuclear medicine departments and healthcare facilities are being established in the country, which is projected to benefit the radiopharmaceuticals market. The rising financial investment from various personal and public healthcare providers are contributing to the growth of the market. In addition, the Japan federal government has made the promotion of nuclear medication sector a priority, with the advancement of regional facilities that make use of nuclear medicine for medical diagnosis and therapy. This is expected to have a favorable impact on the radiopharmaceuticals market expansion.
Growth of the global radiopharmaceuticals market share is majorly driven by rise in prevalence of cancer, cardiovascular, and neurological disease, increase in demand for medical imaging, and rise in product approval for radiopharmaceuticals. For instance, in March 2022, the U.S. Food and Drug Administration (FDA), announced the approval of Locametz (active ingredient gallium Ga 68 gozetotide). It is a radioactive diagnostic agent for positron emission tomography of prostate-specific membrane antigen-positive lesions. Moreover, in March 2022, Novartis, a pharmaceutical company, announced the U.S. FDA approval of Pluvicto, for the treatment of adults with advanced cancer known as prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). The market is growing as result of an increase in radiopharmaceutical R&D activities.
A significant factor driving the radiopharmaceuticals market growth is the alarming rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, and neurology. Radiopharmaceuticals are radioactive drugs that are used to detect and treat cancer cells. They are administered into the body and accumulate in cancerous tissues, allowing for the diagnosis and treatment of the disease. Oncologist also develops interest in radiopharmaceuticals, which contain radioactive particles attached to drugs and aims to target and kill the cancer cells. Around 1.9 million new cancer cases were estimated to have been identified in the U.S. in 2022, according to the American Cancer Society. In addition, the National Cancer Institute reported that around 50% of all cancer patients are prescribed with radiation therapy at some point during their treatment.
The Japan radiopharmaceuticals market is increasingly focusing on brand-new product launches, R&D, and pricing strategies. Major players operating in the market are actively participating in collaborations and mergers & acquisitions to gain a dominant position. This is expected to create several growth opportunities in the market. Firms are additionally focusing on expanding their client base by introducing new products or services.
Key players in the Japan radiopharmaceuticals market are focusing on creating common radiopharmaceuticals, in order to raise their earnings. In addition, developments in technology as well as penetration of these drugs right into the remote areas are expected to bring about a rise in the demand for radiopharmaceuticals. Mergers & acquisitions, collaborations, and various other strategies are likewise being utilized to enhance revenue growth of the market.
In conclusion, the Japan radiopharmaceuticals market is seeing fast development, owing to the raising demand for diagnostic and therapeutic radiopharmaceuticals for cancer cells as well as other illness, technical innovations, and enhanced financial investment from both public and private doctors. Moreover, new product launches, R&D campaigns, collaborations, and increased recognition of nuclear medication are anticipated to boost the market expansion. Because of this, the market is prepared to experience a healthy development during the forecast years.
Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Fujifilm RI Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Yakult Honsha Co., Ltd., Astellas Pharma Inc., Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Japan Radioisotope Association, Japan Pharmaceutical Manufacturers Association are some of the companies operating in the market.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in the Japan radiopharmaceuticals market.
- Assess and rank the top factors that are expected to affect the growth of the Japan radiopharmaceuticals market.
- Top player positioning provides a clear understanding of the present position of market players.
- Detailed analysis of the Japan radiopharmaceuticals market segmentation assists to determine prevailing market opportunities.
- Identify key investment pockets for various offerings in the market
Japan Radiopharmaceuticals Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 85 |
 By Type |
|
 By End User |
|
 By Radioisotope |
|
 By Application |
|
 Key Market Players | Japan Pharmaceutical Manufacturers Association, Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Astellas Pharma Inc., Yakult Honsha Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Fujifilm RI Pharma Co., Ltd., Japan Radioisotope Association, Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. |
The Japan Radiopharmaceuticals Market is projected to grow at a CAGR of 11.4% from 2022 to 2032
Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Fujifilm RI Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Yakult Honsha Co., Ltd., Astellas Pharma Inc., Eisai Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Japan Radioisotope Association, Japan Pharmaceutical Manufacturers Association are the leading players in Japan Radiopharmaceuticals Market
1. Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
2. Analyze the key strategies adopted by major market players in japan radiopharmaceuticals market.
3. Assess and rank the top factors that are expected to affect the growth of japan radiopharmaceuticals market.
4. Top Player positioning provides a clear understanding of the present position of market players.
5. Detailed analysis of the japan radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
6. Identify key investment pockets for various offerings in the market.
Japan Radiopharmaceuticals Market is classified as by end user, by radioisotope, by application, by type
Loading Table Of Content...
Loading Research Methodology...
